0001193125-26-211871
SEC filingRevelation Biosciences reported wider Q1 2026 losses with operating income at -$3.1M (-47.6% YoY) and net income at -$3.0M (-46.7% YoY), reflecting expanded R&D and G&A investments as the company advances product development amid ongoing cash burn.
Revelation Biosciences, Inc. (REVB) reported escalating losses in Q1 FY2026, consistent with its clinical-stage biotechnology focus on product candidates like GEM-AKI and GEM-CKD. Operating income reached -$3.1 million, a 47.6% year-over-year worsening from -$2.1 million in Q1 FY2025. This reflects the company's deliberate expansion of research and development activities, where expenses consist primarily of costs for developing product candidates. Management notes that R&D expenses are expected to increase substantially for the foreseeable future as clinical development continues for current and future candidates. The inherently unpredictable nature of product development prevents reasonable estimation of total costs or timelines to commercialization.